Systemic methotrexate therapy for psoriasis: past, present and future
- 10 July 2013
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 38 (6) , 573-588
Abstract
Methotrexate (MTX) has remained the backbone of the treatment for moderate to severe psoriasis ever since its first use nearly half a century ago. Over the years, its high efficacy, low cost, relative ease of administration and usefulness in concomitant psoriatic arthritis have contributed in making MTX the drug of choice in managing severe psoriasis. Although the majority of patients achieve remission of disease activity with MTX, a significant proportion may experience mild and transient adverse effects. From time to time, various guidelines on the use of MTX have correctly and adequately stressed the need for strict monitoring of haematological and hepatic adverse events. Over the years, the safe total cumulative dose of MTX (above which the risk of developing liver fibrosis is significantly increased) has been raised. Simultaneously, there has been an increased emphasis on developing noninvasive tests such as scanning and serum biomarker assays for detecting early liver fibrosis, in order to obviate the need for liver biopsy. However, the recent discovery and subsequent proliferating use of biological response modifiers has gradually shifted the focus away from MTX, despite it still being the most commonly prescribed drug for psoriasis worldwide. The aim of this review is to present a detailed account of MTX therapy and its use in psoriasis, along with its current relevance in disease management in the evolving era of biological drugs.Keywords
This publication has 99 references indexed in Scilit:
- A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasisBritish Journal of Dermatology, 2012
- Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular DiseaseThe American Journal of Cardiology, 2011
- Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBITArthritis Research & Therapy, 2010
- Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E InitiativeAnnals of the Rheumatic Diseases, 2009
- Medial tibial stress syndrome due to methotrexate osteopathyAnnals of the Rheumatic Diseases, 2006
- Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: A randomized, placebo-controlled studyJournal of the American Academy of Dermatology, 2006
- A clinician's paradigm in the treatment of psoriasisJournal of the American Academy of Dermatology, 2005
- Methotrexate and psoriasis in the era of new biologic agentsJournal of the American Academy of Dermatology, 2004
- Combined methotrexate-PUVA therapy in the treatment of psoriasisJournal of the American Academy of Dermatology, 1982
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)New England Journal of Medicine, 1948